AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3527182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine dihydrochloride (LS group)
Number of subjects: 233
Study 3527182 — intervention group
Group type: COMPARATOR
Intervention: Gefarnate (GF group)
Number of subjects: 233
Study 31274657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative adverse events (near misses)
Number of subjects: 175
Study 31462701 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered report
Number of subjects: 94
Study 31462701 — intervention group
Group type: COMPARATOR
Intervention: Standard report
Number of subjects: 94
Study 30074410 — intervention group
Group type: COMPARATOR
Intervention: Method 1 (informed consent documents mailed prior to visit)
Number of subjects: 520
Study 30074410 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (informed consent documents provided in person at the visit)
Number of subjects: 520
Study 30074410 — intervention group
Group type: COMPARATOR
Intervention: Method 1
Number of subjects: 520
Study 30074410 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2
Number of subjects: 520
Study 30074410 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 and Method 2
Number of subjects: 520
Study 27575409 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab monotherapy (IVM)
Number of subjects: 40
Study 27575409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal combination (IVC) of dexamethasone implant and ranibizumab
Number of subjects: 40
Study 26226350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 24
Study 26226350 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (75mg)
Number of subjects: 24
Study 26226350 — intervention group
Group type: COMPARATOR
Intervention: Combination of nicotine and moclobemide
Number of subjects: 24
Study 24183037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (75 mg clopidogrel + 100 mg aspirin daily)
Number of subjects: 60
Study 24183037 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (100 mg daily)
Number of subjects: 60
Study 21427443 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 12
Study 21427443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18819960 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (5% or greater over 6 months)
Number of subjects: 6933
Study 18819960 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (annual weight loss exceeding 10%)
Number of subjects: 6933
Study 18819960 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 6933
Study 18819960 — intervention group
Group type: COMPARATOR
Intervention: Candesartan treatment
Number of subjects: 6933
Study 17211970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% with the On-Q PAINBUSTER system
Number of subjects: 20
Study 17211970 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine + 120 mg ketorolac + saline solution up to 96 ml with an elastomeric pump i.v.
Number of subjects: 20
Study 14604928 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and proguanil
Number of subjects: 623
Study 14604928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 623
Study 14604928 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 623
Study 14604928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil
Number of subjects: 623
Study 14604928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 10980174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 5 days
Number of subjects: 49
Study 10980174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 10 days
Number of subjects: 49
Study 10980174 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin therapy for 3 days
Number of subjects: 49
Study 8931409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment for 2 years
Number of subjects: 61
Study 8931409 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 2 years
Number of subjects: 61
Study 8931409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 61
Study 8931409 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 61
Study 1422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 45
Study 1422751 — intervention group
Group type: COMPARATOR
Intervention: No ileostomy
Number of subjects: 45
Study 6233547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling a combined preparation of fenoterol 200 micrograms and ipratropium bromide 80 micrograms (Duovent)
Number of subjects: 24
Study 6233547 — intervention group
Group type: COMPARATOR
Intervention: Inhaling 200 micrograms of salbutamol
Number of subjects: 24
Study 6233547 — intervention group
Group type: COMPARATOR
Intervention: Inhaling a similar dose of fenoterol
Number of subjects: 24
Study 30807738 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week group dialogue and empathy intervention
Number of subjects: 88
Study 30807738 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 28878156 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 50
Study 28878156 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine (active comparator)
Number of subjects: 50
Study 25852025 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-SDS breakfasts
Number of subjects: 16
Study 25852025 — intervention group
Group type: COMPARATOR
Intervention: Lo-SDS breakfast
Number of subjects: 16
Study 23771480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention wards (trained in six core strategies for six months)
Number of subjects: 88
Study 23771480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention wards
Number of subjects: 88
Study 23771480 — intervention group
Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 88
Study 21131468 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b
Number of subjects: 822
Study 19266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium under sevoflurane
Number of subjects: 80
Study 19266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium under sevoflurane
Number of subjects: 80
Study 19266825 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium under TIVA
Number of subjects: 80
Study 19266825 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium under TIVA
Number of subjects: 80
Study 19266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 19266825 — intervention group
Group type: COMPARATOR
Intervention: TIVA (Propofol)
Number of subjects: 80
Study 19266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium and Cisatracurium
Number of subjects: 80
Study 18020935 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored dietary fat intake intervention (50-min session)
Number of subjects: 304
Study 18020935 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 304
Study 15074388 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief inventory for diagnosis and monitoring of GORD symptoms
Number of subjects: 558
Study 15074388 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 558
Study 15074388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 558
Study 11237160 — intervention group
Group type: COMPARATOR
Intervention: Leisure therapy
Number of subjects: 466
Study 11237160 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy (OT)
Number of subjects: 466
Study 11237160 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 466
Study 9673264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccine containing pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN)
Number of subjects: 24
Study 9673264 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection with PT and FHA
Number of subjects: 24
Study 9673264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccine
Number of subjects: 24
Study 8079053 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation by emergency medical technicians (EMTs)
Number of subjects: 159
Study 8079053 — intervention group
Group type: COMPARATOR
Intervention: Defibrillation by emergency physicians (EPs)
Number of subjects: 159
Study 2809409 — intervention group
Group type: EXPERIMENTAL
Intervention: Passages with combined semantic and syntactic modifications
Number of subjects: 92
Study 2809409 — intervention group
Group type: EXPERIMENTAL
Intervention: Passages with syntactic modifications alone
Number of subjects: 92
Study 2809409 — intervention group
Group type: EXPERIMENTAL
Intervention: Passages with semantic modifications alone
Number of subjects: 92
Study 2809409 — intervention group
Group type: COMPARATOR
Intervention: Control group reading a social studies passage without change
Number of subjects: 92
Study 812887 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose system (glucose alone)
Number of subjects: 0
Study 812887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid system (83% Intralipid and 17% glucose)
Number of subjects: 0
Study 812887 — intervention group
Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 0
Study 812887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid system
Number of subjects: 0
Study 31196175 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 120
Study 28818057 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling sessions with a physiotherapist during pulmonary rehabilitation (5 sessions)
Number of subjects: 56
Study 28818057 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary rehabilitation program (12 weeks)
Number of subjects: 56
Study 25822691 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Surgical Coaching (CSC)
Number of subjects: 20
Study 25822691 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 20
Study 22866680 — intervention group
Group type: EXPERIMENTAL
Intervention: Making Socially Accepting Inclusive Classrooms (MOSAIC)
Number of subjects: 24
Study 22866680 — intervention group
Group type: COMPARATOR
Intervention: Contingency management training (COMET)
Number of subjects: 24
Study 21296481 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3 lithotripter
Number of subjects: 820
Study 21296481 — intervention group
Group type: COMPARATOR
Intervention: MODULITH® SLX-F2 lithotripter
Number of subjects: 820
Study 18850516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 microg initial dose, followed by 50 microg doses at 3-6 hour intervals)
Number of subjects: 232
Study 18850516 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter and oral misoprostol (100 microg at 4-6 hour intervals)
Number of subjects: 232
Study 18850516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 232
Study 18850516 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter and oral misoprostol
Number of subjects: 232
Study 18850516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol and Foley catheter with oral misoprostol
Number of subjects: 232
Study 17084102 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated lens case
Number of subjects: 80
Study 17084102 — intervention group
Group type: COMPARATOR
Intervention: Standard lens case
Number of subjects: 80
Study 14763920 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral oestradiol plus CPA (n=12)
Number of subjects: 24
Study 14763920 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oestradiol plus CPA (n=12)
Number of subjects: 24
Study 11485131 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 11485131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9164314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1840
Study 9164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg twice a day)
Number of subjects: 1840
Study 9164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus Loviride (150 mg twice a day plus 100 mg three times a day)
Number of subjects: 1840
Study 9164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 1840
Study 9164314 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1840
Study 7696153 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated computer‐assisted image analysis (BIOCOM 500) for BrdU labelling index
Number of subjects: 0
Study 7696153 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated image analysis for estrogen receptor (ER) content
Number of subjects: 0
Study 7696153 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated image analysis for progesterone receptor (PR) content
Number of subjects: 0
Study 3427825 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole limpet haemocyanin (KLH) 250 micrograms
Number of subjects: 120
Study 3427825 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole limpet haemocyanin (KLH) 2.5 mg
Number of subjects: 120
Study 3427825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RV) 170 micrograms
Number of subjects: 120
Study 3427825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RV) 680 micrograms
Number of subjects: 120
Study 3427825 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 120
Study 31782028 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive athletes
Number of subjects: 611
Study 31782028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseball players, cyclists, and wrestlers
Number of subjects: 611
Study 31782028 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball players
Number of subjects: 611
Study 31782028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseball players, cyclists, rowers, and wrestlers
Number of subjects: 611
Study 29976359 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus‐eluting stents
Number of subjects: 1905
Study 29976359 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study 29976359 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1905
Study 29976359 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905
Study 28101631 — intervention group
Group type: EXPERIMENTAL
Intervention: Drill guide technique
Number of subjects: 24
Study 28101631 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 24
Study 25623323 — intervention group
Group type: EXPERIMENTAL
Intervention: High inferior mesenteric artery ligation
Number of subjects: 200
Study 25623323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low inferior mesenteric artery ligation
Number of subjects: 200
Study 24094789 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (12-14 sessions within a 12-week intervention period)
Number of subjects: 0
Study 24094789 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (immediate start group)
Number of subjects: 0
Study 24094789 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (delayed start group)
Number of subjects: 0
Study 24094789 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 20174902 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based physical activity intervention
Number of subjects: 88
Study 20174902 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact control
Number of subjects: 88
Study 17951619 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO measurement with a portable nitric oxide analyzer
Number of subjects: 961
Study 17951619 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO values > 19 ppb
Number of subjects: 961
Study 17951619 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO values > 25 ppb
Number of subjects: 961
Study 17951619 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO measurement
Number of subjects: 961
Study 16977262 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 104
Study 16977262 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 104
Study 16977262 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 104
Study 12950410 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg levofloxacin once a day over 10 days
Number of subjects: 36
Study 12950410 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 36
Study 10888969 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise only
Number of subjects: 133
Study 10888969 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight management program, including exercise
Number of subjects: 133
Study 10888969 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 133
Study 9162608 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 120-min proinsulin response to glucose during initial OGTT
Number of subjects: 59
Study 9162608 — intervention group
Group type: COMPARATOR
Intervention: Initial fasting plasma glucose values
Number of subjects: 59
Study 9162608 — intervention group
Group type: COMPARATOR
Intervention: Initial 120-min plasma glucose values
Number of subjects: 59
Study 8091868 — intervention group
Group type: COMPARATOR
Intervention: 15 mg methotrexate (MTX) per week
Number of subjects: 168
Study 8091868 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg methotrexate (MTX) per week
Number of subjects: 168
Study 2855325 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 121
Study 2855325 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy using three different drug-combinations
Number of subjects: 121
Study 29650440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and macrogol
Number of subjects: 129
Study 29650440 — intervention group
Group type: COMPARATOR
Intervention: Macrogol and matching placebo
Number of subjects: 129
Study 27665002 — intervention group
Group type: EXPERIMENTAL
Intervention: Scattered-site Housing First (SHF) with Assertive Community Treatment
Number of subjects: 165
Study 27665002 — intervention group
Group type: EXPERIMENTAL
Intervention: Congregate Housing First (CHF) with on-site supports
Number of subjects: 165
Study 27665002 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 165
Study 25725780 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 20 ml 0.25 % levobupivacaine (100 mg)
Number of subjects: 40
Study 25725780 — intervention group
Group type: COMPARATOR
Intervention: Non-TAP group (no TAP block)
Number of subjects: 40
Study 23736089 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 23736089 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 20
Study 23736089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AWS
Number of subjects: 20
Study 23736089 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz C‐MAC
Number of subjects: 20
Study 23736089 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger
Number of subjects: 20
Study 23736089 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath Series5
Number of subjects: 20
Study 21483384 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg physostigmine in 250 mL N/S 0.9% (Physo group)
Number of subjects: 80
Study 21483384 — intervention group
Group type: COMPARATOR
Intervention: 250 mL N/S 0.9% placebo (Control group)
Number of subjects: 80
Study 18155759 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Assortment (SY)
Number of subjects: 167
Study 18155759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaper Prompt L‐Pop (PLP)
Number of subjects: 167
Study 18155759 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Gluma inside (IB)
Number of subjects: 167
Study 18155759 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (PB)
Number of subjects: 167
Study 16579002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 40
Study 16579002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 15107914 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoridated dentifrice with 20% sucrose solution dripped 10 times a day
Number of subjects: 13
Study 10688723 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB phototherapy combined with topical tazarotene 0.05% applied once daily
Number of subjects: 10
Study 10688723 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band UVB phototherapy (monotherapy)
Number of subjects: 10
Study 7551562 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 25
Study 7551562 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 25
Study 2394301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid combination (FAC-EC)
Number of subjects: 45
Study 2394301 — intervention group
Group type: COMPARATOR
Intervention: Dimethylfumaric acid esters (DMFAE-EC)
Number of subjects: 45
Study 6997522 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 1012
Study 6997522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study 30716188 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 189
Study 30716188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse counselling
Number of subjects: 189
Study 30716188 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study 30716188 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support and Nurse counselling
Number of subjects: 189